Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice

類似資料

• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
  著者:: Baek, R, 等
  出版事項: (2008)
• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
  著者:: Baek, R, 等
  出版事項: (2004)
• Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
  著者:: Kasperzyk, J, 等
  出版事項: (2002)
• Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice
  著者:: J.L. Kasperzyk, 等
  出版事項: (2005-04-01)
• "Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
  著者:: Kasperzyk, J, 等
  出版事項: (2005)